Jeremy Richardson is the chief commercial officer at Gifthealth.

BIOSECURE is catalyzing structural sourcing and manufacturing shifts, prompting reassessment of legacy partnerships and ...

President Trump’s Most Favored Nation (MFN) drug pricing proposals are awaiting approval by the U.S. Congress. Passage of the ...

Seventy-five executives across manufacturers and agencies backed a unified “system of work” to reduce multi-tool fragmentation across core commercial functions, reflecting a shift from tool ...

Record drug shortages (≥216 active in the US in 2025) expose limited end-to-end visibility, motivating AI-driven early risk detection and coordinated mitigation across fragmented networks.

Pharmaceutical distribution today is anything but monolithic. While companies in this space are grappling with issues ranging from inflation and supply chain disruption to workforce scarcity and DSCSA ...

At the Doceree Makers Summit, leaders from Sanofi, Bristol Myers Squibb, Eli Lilly, and others backed a new pharma marketing operating model to replace fragmented legacy softwares. In today’s Pharma ...

Sources familiar with White House deliberations suggest Makary’s departure is imminent, though neither the White House nor HHS has confirmed or named a successor. Makary’s tenure aligned FDA with MAHA ...

Pharma is moving from centralized patient hub services to a “hubless hub” model, using tech-enabled, distributed access tools to improve speed and outcomes. For decades, pharmaceutical companies have ...

Acting commissioner Kyle Diamantas assumes interim control, prolonging uncertainty until a Senate-confirmed commissioner is installed and governance stabilizes. Elevated leadership churn and perceived ...

Bill McElnea and Hinal Sharma discuss how the role of a specialty pharmacy will evolve in the next few years. In the second part of Pharmaceutical Commerce’s conversation with Bill McElnea, vice ...